Uku Haljasorg

Dr. Uku Haljasorg

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ARAna Rebane
Ana Rebane
TRToomas Runnel
Toomas Runnel
AAAlar Aab
Alar Aab
JMJulia Maslovskaja
Julia Maslovskaja
BRBeate Rückert
Beate Rückert
CACezmi A. Akdis
Cezmi A. Akdis

10 September 2009 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TOTõnis Org
Tõnis Org
ARAna Rebane
Ana Rebane
KKKalle Kisand
Kalle Kisand
MLMartti Laan
Martti Laan
UHUku Haljasorg
Uku Haljasorg
PPPärt Peterson
Pärt Peterson
The Autoimmune Regulator (AIRE) protein is expressed in thymic medullary epithelial cells, where it promotes the ectopic expression of tissue-restricted antigens needed for efficient negative selection of developing thymocytes. Mutations in AIRE cause APECED syndrome, which is characterized by a breakdown of self-tolerance. The molecular mechanism by which AIRE increases the expression of a variety of different genes remains unknown. Here, we studied AIRE-regulated genes using whole genome expression analysis and chromatin immunoprecipitation. We show that AIRE preferentially activates genes that are tissue-specific and characterized by low levels of initial expression in stably transfected HEK293 cell model and mouse thymic medullary epithelial cells. In addition, the AIRE-regulated genes lack active chromatin marks, such as histone H3 trimethylation (H3K4me3) and acetylation (AcH3), on their promoters. We also show that during activation by AIRE, the target genes acquire histone H3 modifications associated with transcription and RNA polymerase II. In conclusion, our data show that AIRE is able to promote ectopic gene expression from chromatin associated with histone modifications characteristic to inactive genes.

23 May 2016 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
MLMartti Laan
Martti Laan
UHUku Haljasorg
Uku Haljasorg
KKKalle Kisand
Kalle Kisand
ASAndres Salumets
Andres Salumets
PPPärt Peterson
Pärt Peterson
During normal pregnancy, the thymus undergoes a severe reduction in size and thymocyte output, which may contribute to maternal–fetal tolerance. It is presently unknown whether the pregnancy‐induced thymic involution also affects nonlymphoid thymic cell populations and whether these changes in stromal cells play a role in the reduction in thymocyte numbers. Here, we characterize the changes in thymic lymphoid and nonlymphoid cells and show that pregnancy results in a reduction of all major thymic lymphoid cell populations, including the early T‐lymphoid progenitors (TLPs) and thymic regulatory T cells. In addition to the thymocytes, the thymic involution also includes all major nonlymphoid cell populations, which show a profound reduction in cell numbers. We also show that during pregnancy, the thymic nonlymphoid cells exhibit decreased expression of chemokines that are essential for TLP homing: CCL25, CXCL12, CCL21, and CCL19. In addition, the expression of these chemokines was substantially downregulated by short‐term treatment with progesterone but not estrogen. Collectively, these findings suggest a novel mechanism for the pregnancy‐induced reduction in TLP homing and the resulting thymic involution.

3 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YGYael Goldfarb
Yael Goldfarb
TGTal Givony
Tal Givony
NKNoam Kadouri
Noam Kadouri
JDJan Dobeš
Jan Dobeš
CPCristina Peligero-Cruz
Cristina Peligero-Cruz
JAJakub Abramson
Jakub Abramson
The autoimmune regulator (AIRE) is essential for the establishment of central tolerance and prevention of autoimmunity. Interestingly, different AIRE mutations cause autoimmunity in either recessive or dominant-negative manners. Using engineered mouse models, we establish that some monoallelic mutants, including C311Y and C446G, cause breakdown of central tolerance. By using RNAseq, ATACseq, ChIPseq, and protein analyses, we dissect the underlying mechanisms for their dominancy. Specifically, we show that recessive mutations result in a lack of AIRE protein expression, while the dominant mutations in both PHD domains augment the expression of dysfunctional AIRE with altered capacity to bind chromatin and induce gene expression. Finally, we demonstrate that enhanced AIRE expression is partially due to increased chromatin accessibility of the AIRE proximal enhancer, which serves as a docking site for AIRE binding. Therefore, our data not only elucidate why some AIRE mutations are recessive while others dominant, but also identify an autoregulatory mechanism by which AIRE negatively modulates its own expression.

1 June 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ILIngrid Liiv
Ingrid Liiv
UHUku Haljasorg
Uku Haljasorg
KKKalle Kisand
Kalle Kisand
JMJulia Maslovskaja
Julia Maslovskaja
MLMartti Laan
Martti Laan
PPPärt Peterson
Pärt Peterson

28 June 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ALAnni Lepland
Anni Lepland
AMAlessio Malfanti
Alessio Malfanti
UHUku Haljasorg
Uku Haljasorg
EAEliana Asciutto
Eliana Asciutto
MPMonica Pickholz
Monica Pickholz
PSPablo Scodeller
Pablo Scodeller
Although many studies have explored the depletion of tumor-associated macrophages (TAM) as a therapeutic strategy for solid tumors, currently available compounds suffer from poor efficacy and dose-limiting side effects. Here, we developed a novel TAM-depleting agent (“OximUNO”) that specifically targets CD206+ TAMs and demonstrated efficacy in a triple-negative breast cancer (TNBC) mouse model. OximUNO comprises a star-shaped polyglutamate (St-PGA) decorated with the CD206-targeting peptide mUNO that carries the chemotherapeutic drug doxorubicin (DOX). In the TNBC model, a fluorescently labeled mUNO-decorated St-PGA homed to CD206+ TAMs within primary lesions and metastases. OximUNO exhibited no acute liver or kidney toxicity in vivo. Treatment with OximUNO reduced the progression of primary tumor lesions and pulmonary metastases, significantly diminished the number of CD206+ TAMs and increased the CD8/FOXP3 expression ratio (indicating immunomodulation). Our findings suggest the potential benefit of OximUNO as a TAM-depleting agent for TNBC treatment. Importantly, our studies also represent a novel design of a peptide-targeted St-PGA as a targeted therapeutic nanoconjugate.Significance: A peptide-targeted nanoformulation of DOX exclusively eliminates mannose receptor+ TAMs in breast cancer models, generating response without off-target effects (a drawback of many TAM-depleting agents under clinical study).